Replies to post #235673 on Biotech Values

[DewDiligence]

TVTX -41% on phase-3 miss:

https://www.businesswire.com/news/home/20230921058683/en

FILSPARI demonstrated long-term kidney function preservation and achieved a clinically meaningful difference in estimated glomerular filtration rate (eGFR) total and chronic slope versus irbesartan, narrowly missing statistical significance in eGFR total slope while achieving statistical significance in eGFR chronic slope for purposes of regulatory review in the EU. FILSPARI is currently available under accelerated approval in the U.S.